I. See Also
II. Indications
-
Major Depression including refractory cases
- Considered to be second-line agent
- Generalized Anxiety Disorder
III. Mechanism
- Similar activity as Tricyclic Antidepressants
- Serotonin Norepinephrine Reuptake Inhibitor
- Selective Serotonin Reuptake Inhibitor (<150 mg/day)
- Norepinephrine Reuptake Inhibitor (>150 mg/day)
- Minimally inhibits Dopamine uptake
IV. Pharmacokinetics
- Half life: 5 to 11 hours
V. Background
- Cost (2013)
- Venlafaxine ER (Effexor XR): $20 per month
- Desvenlafaxine (Pristiq or the ER base): $140-160 per month
VI. Preparations: Venlafaxine
- Venlafaxine regular release (Effexor)
- Available as 25, 37.5, 75, 100 mg tablets (scored)
- Start: 25 mg PO tid
- Effective dose: 150-225 mg per day divided bid to tid
- Maximum dose: 375 mg per day
- Disadvantages: More adverse effects than Effexor XR
- Advantages: May be dosed once daily since metabolites offer similar duration to Effexor XR
- Venlafaxine extended release (Effexor XR)
- Available as 37.5, 75, 150 mg (capsules)
- Start: 37.5 to 75 mg orally daily
- Maximum: 225 mg orally daily
VII. Preparations: Desvenlafaxine
-
Pristiq (Desvenlafaxine Succinate)
- Active metabolite of Effexor XR
- No added benefit over Effexor XR and with possibly more adverse effects
- Reference
- (2008) Prescriber's Letter 15(5): 28
- Desvenlafaxine ER (extended-release base preparation)
- References
- (2013) Presc Lett 20(7):40
VIII. Precautions: Prominent Withdrawal symptoms
- See also Antidepressant Withdrawal
- Dizziness, irritability and Insomnia
- Symptoms start 3 days after stopping medication
- Effexor taper schedule
- Reduce dose 25 mg/day every 5-7 days
- Taper to 25-50 mg/day before stopping
- Effexor XR taper schedule
- Reduce dose 37.5 to 75 mg per day every 7 days
- Taper to 37.5 mg/day before stopping
IX. Adverse Effects (higher with regular release Effexor)
- Anticholinergic (less than Tricyclic Antidepressants)
-
Nausea or Vomiting
- May be severe and limit dosing
- Start therapy at 25 mg per day
- Increased Blood Pressure
- Only seen with total daily doses 300 mg or higher
- Less Sexual Dysfunction than Prozac, Zoloft, Paxil
- Sexual Dysfunction in 10-15% of cases
- Similar to Luvox and Celexa
- See Antidepressant Induced Sexual Dysfunction
- More stimulating (anxiogenic) than sedating
- Agitation or Insomnia may occur
- Decreased appetite and Weight loss may occur
X. Drug Interactions
- Minimal Cytochrome P450 interactions
XI. References
- (1997) Am J Psych 154:1760 [PubMed]
- Sundberg (1995) Depression Primary Care, PGM, p. 45-57
Images: Related links to external sites (from Bing)
Related Studies (from Trip Database) Open in New Window
| venlafaxine (on 10/21/2015 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| VENLAFAXINE HCL 100 MG TABLET | Generic | $0.29 each |
| VENLAFAXINE HCL 25 MG TABLET | Generic | $0.22 each |
| VENLAFAXINE HCL 37.5 MG TABLET | Generic | $0.27 each |
| VENLAFAXINE HCL 50 MG TABLET | Generic | $0.29 each |
| VENLAFAXINE HCL 75 MG TABLET | Generic | $0.25 each |
| VENLAFAXINE HCL ER 150 MG CAP | Generic | $0.18 each |
| VENLAFAXINE HCL ER 150 MG TAB | Generic | $2.50 each |
| VENLAFAXINE HCL ER 225 MG TAB | Generic | $7.18 each |
| VENLAFAXINE HCL ER 37.5 MG CAP | Generic | $0.15 each |
| VENLAFAXINE HCL ER 37.5 MG TAB | Generic | $2.41 each |
| VENLAFAXINE HCL ER 75 MG CAP | Generic | $0.15 each |
| VENLAFAXINE HCL ER 75 MG TAB | Generic | $2.11 each |
| effexor (on 6/1/2015 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| EFFEXOR XR 150 MG CAPSULE | Generic | $0.18 each |
| EFFEXOR XR 37.5 MG CAPSULE | Generic | $0.15 each |
| EFFEXOR XR 75 MG CAPSULE | Generic | $0.15 each |
Ontology: venlafaxine (C0078569)
| Definition (CHV) | a kind of depression treatment drug |
| Definition (NCI_NCI-GLOSS) | An antidepressant drug that is being evaluated for the treatment of hot flashes in women who have breast cancer. |
| Definition (NCI) | A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors. This agent may reduce hormone-related vasomotor symptoms. (NCI04) |
| Definition (CSP) | for the treatment of depression; a norepinephrine reuptake inhibitor |
| Definition (PDQ) | A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors. This agent may reduce hormone-related vasomotor symptoms. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43238&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43238&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1278" NCI Thesaurus) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C047426 |
| SnomedCT | 108432009, 372490001 |
| LNC | LP17950-4, MTHU004272 |
| English | venlafaxine, 1-(2-dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol, venlafaxine [Chemical/Ingredient], VENLAFAXINE, antidepressants venlafaxine, venlafaxine (medication), 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol, Venlafaxine, Venlafaxine (product), Venlafaxine (substance), VNF |
| Spanish | venlafaxina (producto), venlafaxina (sustancia), venlafaxina |
Ontology: Effexor (C0591437)
| Definition (CHV) | a kind of depression treatment drug |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C047426 |
| English | effexor, Effexor, Efexor, Trevilor, Vandral, Wyeth brand of venlafaxine hydrochloride, AHP brand of venlafaxine hydrochloride |

